stockrow
Saturday 7 November 2026
Export DBVT’s income statement to Excel — free account
DBV Technologies S.A.
DBVT Healthcare Biotechnology
DBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024.
- Revenue
- −42.9%
- EPS
- +40.4%
- Free cash flow
- −64.9%
Quarter to September 2026, against a year earlier
10.57
0.77
+7.86%
Follow DBVT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
94.95 | 311.97 | 288.09 | 283.94 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(15.21) | (36.45) | (27.03) | (20.60) | |
P/B ratio |
3.17 | 8.60 | 8.86 | 7.14 | |
Price to Tangible BV |
3.17 | 8.61 | 8.87 | 7.14 | |
EV/Sales |
60.52 | 272.04 | 252.69 | 239.64 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.81) | (10.36) | (7.37) | (4.75) | |
EV/FCF |
(2.80) | (10.30) | (7.31) | (4.67) | |
Quick Ratio |
3.35 | 4.42 | 3.22 | 2.83 | |
Current Ratio |
3.67 | 4.76 | 3.72 | 3.24 | |
Net Debt/EBITDA |
4.38 | 4.89 | 3.50 | 2.58 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.09% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.04 | 0.04 | 0.03 | 0.02 | |
Operating CF/Net income |
0.79 | 1.03 | 1.04 | 0.80 | |
Capex/Depreciation |
(0.49) | (0.44) | (0.67) | (3.67) | |
Interest Coverage |
— | 95.60 | — | — | |
Research and Development Expense of Revenue |
6,134.70% | 3,711.11% | 4,457.14% | 2,937.50% | |
Selling, General and Administrative Expense of Revenue |
2,371.27% | 1,700.00% | 2,871.43% | 1,206.25% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
352.05% | 255.56% | 528.57% | 306.25% | |
Graham Net Nets |
0.28 | 0.11 | 0.10 | 0.12 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(27.57%) | (21.66%) | (21.79%) | (26.27%) | |
Free Cash Flow Yield |
(22.75%) | (8.47%) | (12.00%) | (18.07%) | |
Revenue per Share |
0.02 | 0.01 | 0.01 | 0.02 | |
Operating CF per Share |
(1.26) | (0.57) | (0.61) | (0.57) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
(1.27) | (0.58) | (0.61) | (0.60) | |
Cash per Share |
6.96 | 2.68 | 2.02 | 1.84 | |
Shareholders Equity per Share |
6.05 | 2.43 | 1.85 | 1.65 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.05 | 2.43 | 1.85 | 1.65 | |
Free Cash Flow |
(35.52) | (49.50) | (53.00) | (53.70) | |
Working Capital |
154.90 | 194.90 | 147.60 | 131.10 | |
Capital Expenditures |
(0.34) | (0.40) | (0.40) | (2.20) | |
Net Current Asset Value |
148.00 | 188.30 | 139.10 | 122.90 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.63 | 0.44 | 0.57 | 1.38 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
31.47 | 36.82 | 40.10 | 40.91 | |
Average Assets |
149.68 | 158.48 | 183.31 | 162.95 | |
Average Common Equity |
98.14 | 105.44 | 123.36 | 100.73 |
Columns are period end dates · fundamentals updated 2 Nov 2026